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Short title: GST variants and asthma outcomes in children 
 
 
ABSTRACT 
Our hypothesis was that children with mutations in genes coding for Glutathione S-transferases 
(GST) have worse asthma outcomes compared to children with active type genotype.    Data were 
collected in five populations. The rs1695 single nucleotide polymorphism (GSTP1) was determined in 
all cohorts (3692 children) and GSTM1 and GSTT1 null genotype were determined in three (2362 
children).    GSTT1 null (but not other genotypes) was associated with a minor increased risk for 
asthma attack and there were no significant associations between GST genotypes and asthma 
severity. Interactions between GST genotypes and SHS exposure or asthma severity with the study 
outcomes were non-significant.  We find no convincing evidence that the GST genotypes studied are 
related to asthma outcomes. 
  
INTRODUCTION  
The Glutathione S-transferases (GST) are a family of enzymes which are important for the 
antioxidative defences of many organs in the body including the respiratory system[1],[2].  Asthma is 
a very common chronic respiratory condition characterised by increased oxidative stress[3,4], and in 
adults plasma GST concentration are elevated in asthma[5].  The oxidative burden is further 
increased during an acute attack of asthma[6], and this may indicate an inadequacy of host 
antioxidative properties. 
There are polymorphisms in the genes coding for M, P and T members of the GST family which are 
common and may be relevant to asthma and asthma outcomes.  Approximately 50% of the 
population is null for GSTM1 (i.e. individuals with the null variant have no gene product), 20% is null 
for GSTT1 and 15% is homozygous for the Ile-Val single nucleotide polymorphism (rs1695)[7]. The 
GST variants may be relevant to asthma causation[8-10] and the mechanism may involve 
interactions with oxidative exposures including antenatal[11,12] or postnatal[13,14] second hand 
smoke exposure and air exposures[15-17].   
There is some evidence that GST genotype may be associated with altered risk for asthma attacks 
and severity of asthma is poorly understood, and that interactions with inhaled exposures may also 
be present[7,18].  Among asthmatic children there is evidence of interaction between GST genotype 
and second hand smoke (SHS) for reduced lung function[19] and between GST genotypes and ozone 
exposure for wheeze[20].  One study of 341 families found an association between a GST genotype 
and increased asthma severity score (unpublished data presented in a systematic review[8]) but this 
was not confirmed in two small case-control studies [21,22]. No study has linked GST genotypes to 
asthma attacks.  
The nature of the relationship between GST genotypes and asthma outcomes is subject to 
methodological issues including publication bias, false positive reporting, small sample size and 
multiple testing and the role of genotypes in the genes coding for GST results in disease modification 
is still uncertain[7].  The Pharmacogenomics In Childhood Asthma (PiCA) consortium has come 
together to address these methodological issues[23-25], and   our aim was to use data from a 
number of patient populations within the PiCA consortium and to explore interactions between GST 
genotypes and asthma outcomes.  Our hypothesis is that children with variants in the genes coding 
for GST are at increased odds for attacks and for more severe asthma within a population of children 
with asthma.  In recognition of previous work[13,14], an additional hypothesis was that any 
association between GST genotype and asthma outcomes would be modified by exposure to second 
hand smoke. 
 
SUBJECTS AND METHOD 
Cohorts. Four cohorts of children with asthma provided individual patient data (IPD) and summary 
statistics were provided from a fifth cohort.  The four cohorts were BREATHE (no acronym), recruited 
from primary and secondary care in North East Scotland[19]; Pharmacogenetics of Asthma 
medication in Children: Medication with Anti-inflammatory effects (PACMAN), recruited from 
children attending community pharmacies in the Netherlands[26]; the Paediatric Asthma Gene 
Environment Study (PAGES), recruited from primary and secondary care across Scotland[27]; and in 
the Swedish population birth cohort BAMSE (Swedish abbreviation for Children, Allergy, Milieu, 
Stockholm, Epidemiology), asthmatic children were included[28]. Summary statistics were provided 
from a fifth study, the Genes-environment and Admixture in Latino Americans study (GALA II), 
consisting of children diagnosed with asthma in the US with four grandparents of Latino 
ancestry[29].  More details of the inclusion criteria for the five cohorts are presented in the 
supplement.    
Genotyping. The genotypes of interest were the GSTM1, GSTT1 null genotype and homozygous 
genotype for the substitution of isoleucine with valine at the 105 position of the gene coding for 
GSTP1 (rs1695 single nucleotide polymorphism). For PACMAN, BREATHE and PAGES, saliva for DNA 
extraction was collected using the Oragene system (DNA Genotek ref. OG-250) and specimens were 
processed following the manufacturer’s protocol. GSTM1 and GSTT1 null mutations were 
determined by polymerase chain reaction and GSTP1 polymorphism by an allelic discrimination 
assay as previously described6. For GALA II, DNA was extracted from whole blood before an array 
(Axiom® LAT1, World Array 4, Affymetrix, Santa Clara, CA) was used to determine genome wide-
genotype data.  In BAMSE, GSTP1 was genotyped by matrix-assisted laser desorption/ionization–
time of flight (MALDI-TOF) mass spectrometry (Sequenom)[28]. 
Definition of outcomes. In PACMAN, the definition of attacks was reported use of oral prednisolone 
and/or asthma-related ER visits in the previous 12 months.  For GALA II, the definition of attack was 
at least one of the following in the previous 12 months: oral prednisolone treatment, receiving 
emergency care or admission to hospital for asthma symptoms.  BREATHE and PAGES used the same 
attack definition, which was at least one of the following in the previous six months: receipt of oral 
corticosteroid treatment, absence from school or hospital admission for asthma. For BAMSE an 
attack was defined as an asthma related emergency room and/or asthma-related hospital visit in the 
previous 12 months.  
Asthma severity was determined by treatment step as described in the British Thoracic 
Society/Scottish Intercollegiate Guidelines Network [BTS/SIGN] treatment step[30].  There were very 
few children on step 5 treatment and a composite step 4/5 group was created.  
Children with at least one parent who smoked were categorised as smoke exposed.  Smoking 
exposure was validated by salivary cotinine in 139 participants of the PAGES cohort where median 
(standard error of mean) cotinine for children with no, one and two resident smokers was 0.5 ng/ml 
(0.04), 0.58 ng/ml (0.16) and 1.39 (0.95) respectively, Kruskal Wallace test p < 0.001[27].  
Statistical analysis and power calculation. IPD analysis was undertaken for the PACMAN, BREATHE, 
PAGES and BAMSE cohorts. Age (measured in years), gender (female coded as 1 and male coded as 
0), exposure to second hand smoke (SHS - coded 1 for presence of or 0 for absence of as per 
definitions above), cohort of origin (PACMAN coded as 1, BREATHE coded as 2 and PAGES coded as 
3). Genotypes for GSTM1 and GSTT1 were coded 1=null and 0=active type.  For GSTP1, the 
homozygous valine genotype was coded 1 while the heterozygous and homozygous isoleucine 
rs1695 genotypes were combined and coded 0. To explore the effect of second hand smoke (SHS) on 
the relationship between genetotype and attack, where associations between outcomes and 
genotype were significant, an interaction term between the genotype and SHS was calculated.   
A logistic regression model was used to investigate the factors affecting risk of attacks. A 
multinomial regression model was used to investigate the relationship between BTS/SIGN treatment 
step (with BTS/SIGN treatment step 1 as the reference group). 
To utilise all applicable genotype data within the PiCA consortium, meta-analysis of GSTP1 data from 
IPD analysis of the BREATHE, PACMAN, PAGES and BAMSE populations with the GALA II population 
was performed using a random effects inverse variance–weighted model for the attacks outcome, 
where the individual study ORs are weighted by their confidence intervals. The I2 statistic was 
calculated to examine the heterogeneity in the population. This meta-analysis was implemented 
using the GWAMA software[31].  Details of the power calculation (table 1) and further details of the 
statistical analysis are presented in the supplement. 
 
RESULTS 
Study subjects 
Table 1 presents details of the 3,692 individuals included in the analysis. Details of all three GST 
variants were available in 2197 individuals, including 983 from BREATHE, 719 from PACMAN and 495 
from PAGES.  Additionally, GSTP1 details were available in 165 BAMSE and 1,330 GALA II 
participants.     
Factors associated with an asthma attack 
Out of 3,692 patients, 1,178 patients (36%) experienced at least one asthma attack as per the 
definitions described. Individuals who were GSTT1 null had an increased odds ratio (OR) for an 
asthma attack (OR 1.20 [1.03, 1.59], p=0.03), independent of age, second hand smoke exposure and 
asthma severity (supplement table 2).  There was no association between GSTM1 null (supplement 
table 2) or being homozygous for Val for rs1695 (supplement table 3) and risk for asthma attack.  
The interaction term between GSTT1 and exposure to SHS approached significance (OR - 1.53 [0.98, 
2.38], p=0.06). When analysed separately, individuals null for GSTT1 were at increased risk for an 
asthma attack when also exposed to SHS (1.60 [1.06, 2.43] p=0.02 whereas those with active GSTT1 
were not at increased risk (1.15 [0.88, 1.51] p=0.30)  
There was no association between GSTP1 genotype and risk for asthma attack in the meta-analysis 
The meta-analysed OR [95% CI] was 0.99 [0.81, 1.21]. An I2 value of 0 showed no heterogeneity was 
present in the population.  Results from each individual cohort are presented in supplement table 2. 
Factors associated with severity 
BTS/SIGN treatment step information was available for 3,382 patients, of which 512 (15%), 1,767 
(52%), 792 (24%) and 311 (9%) were being prescribed medications that categorised them into 
BTS/SIGN treatment steps 1, 2, 3 and 4/5 respectively.  In the univariate analysis, there was a trend 
for GSTM1 null genotype to be potentially associated with the odds of severity (p=0.08), this was 
driven by significantly decreased odds of BTS/SIGN treatment step 2 (OR 0.79 [0.64, 0.98] p=0.043, 
see supplement table 4) but this association was clearly non-significant when adjusted for age and 
exposure to second hand smoke.  The interaction between GSTM1 and SHS exposure showed no 
evidence of association with severity (p=0.90).  Neither GSTT1 (p=0.63) or GSTP1 (p=0.43) genotype 
showed evidence of association with severity.  
 
 
DISCUSSION 
There is a plausible mechanism whereby variations in the genes coding for GST could modify asthma 
outcomes in the context of an environment containing an increased oxidative burden (such as SHS 
exposure), but current understanding is restricted by methodological factors including heterogeneity 
between populations, power and multiple testing[7,18].  Our study has addressed many of these 
methodological issues by focussing on populations of children with asthma, demonstrating adequate 
sample size and by undertaking IPD analysis.   
The first finding was that in a multivariable model, GSTT1 null genotype was associated with an 
increased risk of attack, however this was of small magnitude and borderline significance. The 
second notable finding was that children null for GSTM1 had a borderline significant reduction (and 
biologically implausible) OR for step 2 treatment in the multinomial model but in not the 
multivariable model.  Our third and final finding was that despite SHS exposure being associated 
with both outcomes, there were no statistically significant interactions with GSTT1 for asthma 
attacks and GSTM1 for asthma severity.  The well-recognised heterogeneity of asthma is thought to 
be due to disease-modification by within-population variations in genetic and environmental 
factors[32], but in our study the GST variants studied were not consistently linked to asthma 
outcomes. 
There are a number of reasons why there may be no association between the GST variants studied 
and asthma outcomes.  First, there may be no association and factors other than GST are more 
important to lung antioxidative properties, and publication bias may have led to the literature 
predominantly containing studies which find an association (either with increased or occasionally 
reduced[33,34] risk for asthma outcomes) whereas studies which find no association are not 
submitted or accepted for publication.  Second, whilst a power calculation indicates that the 
population was of adequate size to detect an OR of 1.3 with >92% power for the variants studied, 
there may be a smaller effect size associated with an interaction with smoking.  Third, even though 
the variants studied here have been linked with asthma causation and some asthma outcomes in 
other studies, we may have not studied the most relevant GST variants.  Finally, no standard 
definition of an asthma attack was applied across the five populations studied and this may have 
weakened any relationship between the genotypes studies and asthma attack, however despite this 
weakness an association was determined for GSTT1.   
Whilst variants in the genes coding for GST are thought to be important to disease causation and 
modification, the underlying mechanism(s) are still not fully understood and our study suggests that 
the relevance of the GST variants studied to asthma attacks and severity in children is either small or 
none at all.  Plasma GST concentrations are not different between individuals carrying active type or 
mutations of GSTM1, GTSP1 and GSTT1[5,35] but concentrations within the lung correlate with 
rs1695 status[2] suggesting that genetic polymorphisms are important to GST activity within the 
lung.  It is possible that the reduction in GST activity related to mutations of the three genes studied 
is either not sufficient to have clinical relevance for children with asthma and/or the populations 
studies did not experience a burden of oxidative stress sufficient to make the reduced GST activity 
important. 
There are no studies, which are directly comparable to our findings.  Rs 1695[13] and GSTM1 null[14] 
genotypes have been associated with increased risk for asthma diagnosis, but we find no increased 
risk for adverse asthma outcomes for these variants within asthmatic populations. Three studies 
have identified associations between homozygous val genotype rs 1695[15,17,20] and increased risk 
for asthma symptoms in association with ozone exposure, and we did not record ozone exposure in 
our study.  A third study of 43 children with asthma found that there was no difference daily peak 
flow measurements between those null for GSTT1 or GSTM1 in the context of air pollution 
exposure[36], and our results are consistent with these findings.   A previous report from the 
BREATHE cohort has described reduced lung function among older children with asthma with were 
null for GSTM1 and homozygous for valine for GSTP1 and who were exposed to second hand 
smoke[19]; we do not report lung function outcomes in the present paper and no direct comparison 
can be made.   
There are a number of factors which should be considered when interpreting these results.  The 
strengths of our study include the relatively large sample size and the inclusion of more than one 
population.  One potential limitation is that we did not adjust for ethnicity and our  cohorts included 
children of European and Hispanic ethnicity and this introduced a small difference in the distribution 
of GSTP1 genotype between populations (table 1), however in the meta analysis there was no 
heterogeneity in the relationship between this genotype and the outcomes studied and in the IPD 
for GSTT1 and GSTM1 the cohort was included as a covariate which will mitigate against any 
differences in ethnicity between populations affecting the relationship between genotype and 
outcome..  Second, we have focussed on only three genotypes and many genes, e.g. NQO1, HMOX, 
may be relevant to host antioxidative status either individually or in combination[18].  Third, SHS 
exposure was by report in four cohorts and thus may be unreliable, but SHS exposure was validated 
by salivary cotinine in the PAGES cohort[27]. Fourth, we have not related GST variants to objective 
markers of asthma such as lung function.  Finally, in our study the exposure of interest was SHS and 
we did not consider other exposures, e.g. ozone[20], nitrogen dioxide[37], vitamin C[38], which 
might have modified the effect of SHS in genetically-susceptible individuals.   
In summary, we find no evidence for there being an important association between the GST variants 
we have studied and adverse asthma outcomes in children.  We believe that the associations 
between the GSTT1 null variant and asthma attacks and GSTM1 null variant and asthma severity are 
false positive findings.  Our findings are based on a large number of children from more than one 
population, meaning that our findings may be generalisable across similar populations[39].    
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Table 1.  Details of the participants from the five cohorts whose data were used in this study.    
NA=not available 
 BREATHE 
n=1459 
 
PACMAN 
n=996 
PAGES 
n=970 
GALA II 
n=1330 
BAMSE 
n=165 
% Male sex (n) 60%  
(592) 
64%  
(458) 
59%  
(284) 
58% 
(772) 
60.6%  
(100) 
Mean age in years (SD) 9.6 (3.8) 8.4 (2.4) 9.5 (3.8) 11.9 (2.7) 8.3 (0.45) 
% exposed to second hand smoke 
at home (n) 
36%  
(337) 
10% 
(69) 
23%  
(107) 
21% 
(283) 
21.8%          
(36) 
% with recent attack (n) 44% (430) 9% (59) 60% (261) 66% (884) 10% (17) 
GSTM1 status % Active type 52% (508) 49% (351) 45% (223) NA NA 
% Null 48% (475) 51% (368) 55% (272) NA NA 
GSTT1 status % Active Type 79% (777) 78% (564) 79% (393) NA NA 
% Null 21% (206) 22% (155) 21% (102) NA NA 
 
GSTP1 status 
Ile/Ile 40% (395) 40% (287) 45% (222) 34% (453) 46% (76) 
Ile/Val 47% (459) 46% (329) 42% (209) 46% (615) 46.7% (77) 
Val/Val 13% (129) 14% (103) 13% (64) 20% (262) 7.3% (12) 
Number of 
GST mutants 
0 34% (331) 33% (240) 33% (163) NA NA 
1 51% (504) 48% (346) 47% (232) NA NA 
2 14% (138) 17% (119) 19% (94) NA NA 
3 1% (10) 2% (14) 1% (6) NA NA 
 
BTS/SIGN 
treatment 
step  
No treatment or 1 16% (147/945) 14% (93/674) 8% (35/456) 49% (649/1330) 40.0%(66) 
2 55% (523/945) 62% (418/674) 25% (115/456) 21% (283/1330) 59.3%(98) 
3 16% (147/945) 18% (123/674) 55% (251/456) 9% (123/1330) 0.6% (1) 
4 or 5 14% (128/945) 6% (40/674) 12% (55/456) 21% (275/1330) 0 
 
 
 
